Overview
The EUR 60M Series B led by Ackermans and van Haaren, one of Belgium's most respected listed investment holding companies, provides Confo Therapeutics with significant capital to advance its pipeline of GPCR-targeted drugs.
Confo Therapeutics was founded in Ghent as a VIB spin-off, applying proprietary conformational antibody technology to stabilize and drug GPCRs (G protein-coupled receptors), a class of protein targets that are implicated in a wide range of diseases but are notoriously difficult to work with in drug discovery.
The Series B is a major milestone for Ghent's life sciences cluster and validates the commercial potential of VIB-derived platform technologies. Ackermans and van Haaren's direct lead of a biotech round is notable, as the holding company more typically invests in mature industrial and services businesses.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.